BNB Plus Corp. Finalizes Landmark $1.2 Million LineaDNA™ Order
BNB Plus Corp. has announced a significant operational milestone through its biopharmaceutical subsidiary, LineaRx, Inc., which has successfully completed the largest commercial order in its history. The achievement not only highlights the company’s growing role in the genetic medicine supply chain but also reinforces the scalability and reliability of its proprietary LineaDNA platform.
The order, valued at approximately $1.2 million, was initially disclosed in January 2026, with production and shipment concluding in early May 2026. Beyond its financial significance, the project stands out for its execution quality. According to the company, the entire production process was completed with zero batch failures, a notable accomplishment in the highly complex field of DNA manufacturing. This level of consistency underscores the robustness of the LineaDNA platform, particularly in large-scale, cell-free DNA production.
One of the most striking aspects of the project was the production cadence achieved during fulfillment. LineaRx reported sustaining output levels exceeding 1.5 grams of DNA per week, marking a new internal record. This milestone demonstrates not only the platform’s scalability but also its readiness for commercial deployment at higher volumes. In an industry where production bottlenecks and variability can significantly impact downstream applications, such performance is a strong indicator of manufacturing maturity.
Cell-free DNA production platforms like LineaDNA are increasingly critical to the advancement of next-generation therapeutics and diagnostics. These technologies enable the synthesis of high-quality DNA without relying on traditional cell-based systems, which can be time-consuming and prone to variability. By eliminating the need for living cells, cell-free systems offer greater control, faster turnaround times, and improved reproducibility—attributes that are particularly valuable in areas such as gene therapy, mRNA-based treatments, and advanced diagnostic assays.
Clay Shorrock, President and Chief Executive Officer of BNB Plus, emphasized the importance of this milestone for both the subsidiary and the broader organization. He noted that the successful completion of the order reflects growing demand for LineaDNA from leading developers in genetic medicine and in vitro diagnostics. This demand signals increasing industry confidence in the platform’s capabilities, as well as its potential to support a wide range of applications, from therapeutic development to clinical testing.
Shorrock also highlighted the company’s ability to execute consistently at scale as a key differentiator. In the competitive landscape of biomanufacturing, reliability and reproducibility are essential for building long-term partnerships with pharmaceutical and biotechnology companies. The zero batch failure rate achieved during this project serves as a powerful validation of LineaRx’s operational processes and quality control systems.
The implications of this achievement extend beyond a single order. As the global demand for genetic medicines continues to rise, driven by advances in gene editing, personalized medicine, and molecular diagnostics, the need for scalable and dependable DNA manufacturing solutions is becoming increasingly urgent. Platforms like LineaDNA are well-positioned to address this need, offering a flexible and efficient alternative to traditional production methods.
In parallel with this operational success, BNB Plus is currently undergoing a strategic review process aimed at maximizing shareholder value. As previously announced on April 20, 2026, the company’s Board of Directors authorized a formal evaluation of strategic alternatives. These may include potential partnerships, acquisitions, divestitures, or other corporate transactions designed to enhance the company’s long-term growth prospects and financial performance.
While the review is ongoing, the company has indicated that it remains fully committed to executing its existing strategic and operational initiatives. The continued progress of LineaRx, particularly in achieving major commercial milestones such as this one, is expected to play a central role in the evaluation process. The strong fundamentals of the subsidiary—including its proven technology, growing customer base, and demonstrated ability to scale—are likely to be key considerations as the Board assesses potential paths forward.
Shorrock reiterated that the success of LineaRx will be a focal point in the company’s strategic deliberations. The subsidiary’s performance not only enhances the overall value proposition of BNB Plus but also positions the company as an attractive partner or acquisition target within the rapidly evolving biotechnology sector.
At the same time, BNB Plus has adopted a measured approach to communications regarding the strategic review. The company has stated that it does not intend to provide updates until a specific transaction has been approved by the Board or until disclosure is otherwise deemed necessary or legally required. This approach reflects standard practice in corporate governance, ensuring that any announcements are made with appropriate clarity and certainty.
It is important to note that there is no guarantee that the strategic review will result in a transaction. However, the combination of strong operational performance and a clear strategic focus places BNB Plus in a favorable position as it explores its options.
In summary, the successful completion of LineaRx’s largest-ever order represents a defining moment for both the subsidiary and its parent company. By demonstrating high-margin production, zero batch failures, and record-setting output levels, LineaRx has validated the commercial readiness of the LineaDNA platform. Coupled with the ongoing strategic review, this achievement underscores BNB Plus’s commitment to growth, innovation, and value creation in the dynamic field of genetic medicine.
About BNB Plus Corp.
BNB Plus unlocks streamlined access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company’s differentiated strategy blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space. Formerly Applied DNA Sciences, Inc., BNB Plus continues to commercialize the Company’s proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
About LineaDNA
LineaDNA is LineaRx’s proprietary cell-free DNA production platform offering a superior alternative to conventional plasmid-based methods. Leveraging the company’s expertise in large-scale PCR, LineaDNA produces high-fidelity DNA free of adventitious sequences with rapid scalability and chemical modification compatibility. The platform generates DNA constructs from 100 base pairs to 20 kilobases in quantities from milligrams to grams under RUO, GLP, and GMP quality standards, serving genetic medicine and diagnostic markets.
Source Link:https://www.businesswire.com/
